CD8A and neoplasm: To elucidate whether tumor neo-epitopes provided a basis for tumor immune recognition, we stimulated CD8+ peripheral blood lymphocytes (PBLs) with pools of predicted peptides for 12 days in vitro, followed by rechallenge with the same peptides and analysis by IFNγ ELISpot.